Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma

Amy Skorupa, Matthew Beldner, Andrew Kraft, Alberto J. Montero

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.

Original languageEnglish (US)
Pages (from-to)1015-1017
Number of pages3
JournalCancer Biology and Therapy
Volume6
Issue number7
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

trabectedin
Rhabdomyolysis
Sarcoma
Drug Therapy
Palliative Care
Electrolytes
Renal Insufficiency
Skeletal Muscle
Necrosis
Muscles

Keywords

  • Ecteinascidin-743 (Yondelis)
  • Rhabdomyolysis
  • Sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. / Skorupa, Amy; Beldner, Matthew; Kraft, Andrew; Montero, Alberto J.

In: Cancer Biology and Therapy, Vol. 6, No. 7, 07.2007, p. 1015-1017.

Research output: Contribution to journalArticle

Skorupa, Amy ; Beldner, Matthew ; Kraft, Andrew ; Montero, Alberto J. / Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. In: Cancer Biology and Therapy. 2007 ; Vol. 6, No. 7. pp. 1015-1017.
@article{48a4d7ddd4c24ff4b48a9382b5b8a6e2,
title = "Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma",
abstract = "Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.",
keywords = "Ecteinascidin-743 (Yondelis), Rhabdomyolysis, Sarcoma",
author = "Amy Skorupa and Matthew Beldner and Andrew Kraft and Montero, {Alberto J.}",
year = "2007",
month = "7",
language = "English (US)",
volume = "6",
pages = "1015--1017",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "7",

}

TY - JOUR

T1 - Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma

AU - Skorupa, Amy

AU - Beldner, Matthew

AU - Kraft, Andrew

AU - Montero, Alberto J.

PY - 2007/7

Y1 - 2007/7

N2 - Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.

AB - Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.

KW - Ecteinascidin-743 (Yondelis)

KW - Rhabdomyolysis

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=42449133375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449133375&partnerID=8YFLogxK

M3 - Article

C2 - 17611408

AN - SCOPUS:42449133375

VL - 6

SP - 1015

EP - 1017

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 7

ER -